Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial

Ann-Brit Eg Hansen; N Obel; H Nielsen; C Pedersen; J Gerstoft

doi:10.1111/j.1468-1293.2010.00864.x

Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial

Ann-Brit Eg Hansen, N Obel, H Nielsen, C Pedersen, J Gerstoft

56 Citationer (Scopus)

Abstract

The aim of the study was to compare changes in bone mineral density (BMD) over 144 weeks in HIV-infected patients initiating nucleoside reverse transcriptase inhibitor (NRTI)-sparing or protease inhibitor-sparing highly active antiretroviral therapy (HAART).

Originalsprog	Engelsk
Tidsskrift	HIV Medicine
Vol/bind	12
Udgave nummer	3
Sider (fra-til)	157-65
Antal sider	9
ISSN	1464-2662
DOI	https://doi.org/10.1111/j.1468-1293.2010.00864.x
Status	Udgivet - 1 mar. 2011

Adgang til dokumentet

10.1111/j.1468-1293.2010.00864.x

Andre filer og links

Link to publication in Scopus

Citationsformater

Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial. / Hansen, Ann-Brit Eg; Obel, N; Nielsen, H et al.
I: HIV Medicine, Bind 12, Nr. 3, 01.03.2011, s. 157-65.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

@article{b480eb971f6248d6b4f36f9e11e49fff,

title = "Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial",

abstract = "The aim of the study was to compare changes in bone mineral density (BMD) over 144 weeks in HIV-infected patients initiating nucleoside reverse transcriptase inhibitor (NRTI)-sparing or protease inhibitor-sparing highly active antiretroviral therapy (HAART).",

keywords = "Absorptiometry, Photon, Adult, Antiretroviral Therapy, Highly Active, Benzoxazines, Bone Density, Female, HIV Infections, HIV-1, Humans, Lamivudine, Male, Pyrimidinones, Ritonavir, Zidovudine",

author = "Hansen, \{Ann-Brit Eg\} and N Obel and H Nielsen and C Pedersen and J Gerstoft",

note = "{\textcopyright} 2010 British HIV Association.",

year = "2011",

month = mar,

day = "1",

doi = "10.1111/j.1468-1293.2010.00864.x",

language = "English",

volume = "12",

pages = "157--65",

journal = "HIV Medicine",

issn = "1464-2662",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "3",

}

TY - JOUR

T1 - Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial

AU - Hansen, Ann-Brit Eg

AU - Obel, N

AU - Nielsen, H

AU - Pedersen, C

AU - Gerstoft, J

PY - 2011/3/1

Y1 - 2011/3/1

N2 - The aim of the study was to compare changes in bone mineral density (BMD) over 144 weeks in HIV-infected patients initiating nucleoside reverse transcriptase inhibitor (NRTI)-sparing or protease inhibitor-sparing highly active antiretroviral therapy (HAART).

AB - The aim of the study was to compare changes in bone mineral density (BMD) over 144 weeks in HIV-infected patients initiating nucleoside reverse transcriptase inhibitor (NRTI)-sparing or protease inhibitor-sparing highly active antiretroviral therapy (HAART).

KW - Absorptiometry, Photon

KW - Adult

KW - Antiretroviral Therapy, Highly Active

KW - Benzoxazines

KW - Bone Density

KW - Female

KW - HIV Infections

KW - HIV-1

KW - Humans

KW - Lamivudine

KW - Male

KW - Pyrimidinones

KW - Ritonavir

KW - Zidovudine

UR - https://www.scopus.com/pages/publications/79551583044

U2 - 10.1111/j.1468-1293.2010.00864.x

DO - 10.1111/j.1468-1293.2010.00864.x

M3 - Journal article

C2 - 20722752

SN - 1464-2662

VL - 12

SP - 157

EP - 165

JO - HIV Medicine

JF - HIV Medicine

IS - 3

ER -

Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater